News Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
79.84 ^USD	+23.29%		+16.35%	+11.48%

01:00pm	Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	CI
Mar. 19	Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Intra-Cellular Therapies, Inc. - Special Call	08:30am
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	07:01am	AQ
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	07:00am	CI
Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President	Mar. 19	MT
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes	Mar. 19	AQ
Intra-Cellular Therapies, Inc. Announces Executive Changes	Mar. 19	CI
Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer	Mar. 19	CI
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences	Mar. 06	AQ
Intra-Cellular Therapies Insider Sold Shares Worth $1,458,650, According to a Recent SEC Filing	Feb. 29	MT
Intra-Cellular Therapies Insider Sold Shares Worth $1,808,253, According to a Recent SEC Filing	Feb. 28	MT
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference	Feb. 27	AQ
Needham Adjusts Intra-Cellular Therapies Price Target to $82 From $72, Maintains Buy Rating	Feb. 23	MT
Transcript : Intra-Cellular Therapies, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Intra-Cellular Therapies Q4 Loss Narrows, Revenue Increases	Feb. 22	MT
Intra-Cellular: Q4 Earnings Snapshot	Feb. 22	AQ
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q4 Revenue $132.1M	Feb. 22	MT
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update	Feb. 22	AQ
Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 22	CI
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Summary

Filters